Home > News > Clinical Aspects of Continuous Glucose Monitoring
Diabetes
Read Time: 2 mins

Clinical Aspects of Continuous Glucose Monitoring

Published Online: June 6th 2011 European Endocrinology, 2010;6(2):26-30 DOI: http://doi.org/10.17925/EE.2010.06.02.26
Authors: Nina Verheyen, Jens Gios, Christophe De Block
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Abstract
In patients with diabetes, strict glycaemic control is warranted to achieve an improvement in metabolic outcome. When performing self-monitoring of blood glucose, hypo- and hyperglycaemic excursions can be missed. Continuous glucose monitoring (CGM) provides a complete picture of the patient’s glucose levels throughout the day. CGM may also warn against impending glycaemic excursions, thereby reducing the fear of hypoglycaemia and improving the patient’s quality of life. Patients with brittle diabetes, hypoglycaemia unawareness or gastroparesis, pregnant women with diabetes and those who are critically ill may particularly benefit from CGM. Patients and care-givers must be highly motivated, technologically adept and aware of the limitations of CGM devices to successfully use this type of monitoring in daily practice. The impact of CGM on metabolic control, incidence of hypoglycaemia, chronic complications and quality of life needs further investigation.

Keywords
Continuous glucose monitoring (CGM), diabetes, metabolic control

Disclosure: The authors have no conflicts of interest to declare.
Received: 1 June 2009 Accepted: 9 November 2009 Citation: European Endocrinology, 2010;6(2):26–30
Correspondence: Christophe De Block, Department of Endocrinology–Diabetology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium. E: christophe.deblock@ua.ac.be

Article:

More than 15 years have elapsed since the publication of major studies that clearly demonstrated the benefit of aggressive glycaemic control in persons with diabetes.1–3 Currently, frequent self-monitoring of blood glucose (SMBG) is required to achieve tight glycaemic control.4 However, SMBG does not provide information about the direction, magnitude, duration, frequency and causes of fluctuations in blood glucose values.

More than 15 years have elapsed since the publication of major studies that clearly demonstrated the benefit of aggressive glycaemic control in persons with diabetes.1–3 Currently, frequent self-monitoring of blood glucose (SMBG) is required to achieve tight glycaemic control.4 However, SMBG does not provide information about the direction, magnitude, duration, frequency and causes of fluctuations in blood glucose values. Moreover, the fear of hypoglycaemia has a significant impact on patient quality of life and therefore remains a major barrier to achieving optimal glycaemic control. Whereas SMBG takes only a snapshot, continuous glucose monitoring (CGM) provides a complete motion picture of glucose values throughout the day.5–7 In this way CGM, may prove to be an important asset in future diabetes care. This review addresses advantages and limitations of CGM and the target population.

Advantages of Continuous Glucose Monitoring

Metabolic Control

CGM systems provide the patient and the treating physician with a complete picture of glucose levels throughout the day. They can be used either as a Holter system (retrospectively) or as a realtime monitor.5–8 CGM readings may facilitate the making of specific therapeutic adjustments to improve metabolic control. These adjustments can be based either on retrospective analysis and pattern recognition or on realtime data verified by SMBG. It will also be possible to take preventative measures by warning the patient against impending hypo- and hyperglycaemic excursions.8,9

A number of non-randomised, uncontrolled trials have documented improvement of glycated haemoglobin (HbA1c ) and glycaemic excursions (see Table 1).10–19 A total of 13 randomised controlled trials (RCTs) of CGM on metabolic control have been published to date (see Table 1).20–32 In 12 RCTs, HbA1c was used as the primary end-point. Seven RCTs used CGM in retrospect and only one study showed improvement in HbA1c compared with standard SMBG monitoring.23 Five RCTs used realtime CGM, making dynamic adjustments in insulin therapy based on realtime CGM data and verifying measurements with SMBG. All showed improvement of HbA1c levels compared with standard SMBG, except one.25 Realtime CGM reduced glycaemic variability and decreased the time spent in hypo- and hyperglycaemia.21,27,28,31

Recently, the results of the RCT sponsored by the Juvenile Diabetes Research Foundation (JDRF) were published.32 In this multicentre clinical trial, 322 adults, adolescents and children with type 1 diabetes who were already receiving intensive insulin therapy were randomly assigned to a group with realtime CGM or to a control group performing SMBG. This study showed a significant between-group difference in the change in HbA1c from baseline to week 26 in patients who were 25 years of age or older, favouring the CGM group (-0.71 versus -0.35%).32In addition, more patients in the CGM group had a relative reduction of 10% or more in mean HbA1c levels and a higher number achieved the target HbA1c level of <7.0%. The percentage of time per day within the target glucose range of 70–180mg/dl was significantly greater in the CGM group. Among patients who were 15–24 years of age, no significant differences in any of the glycaemic measures were observed between groups.32 However, only 30% of these patients used CGM on six or more days per week compared with 83% in patients 25 years of age or older. Among patients who were eight to 14 years of age, the mean decrease in HbA1c levels was 0.38% in the CGM group, which did not differ significantly from the control group. However, secondary indices of glycaemic control were improved in the CGM group, with more patients having a relative reduction of 10% or more in HbA1c levels and more achieving the target HbA1c level of <7.0%.32
In addition to HbA1c, glucose variability may be an important parameter in metabolic control and even a predictor of diabetic complications.33 Many hyper- and hypoglycaemic spikes may cancel each other out in terms of altering HbA1c levels. By making therapeutic adjustments based on trend information, realtime CGM may enable patients to reduce glycaemic variability and increase the time spent in normoglycaemia.17,34 Patients with a wide variability in blood glucose concentrations (brittle diabetes) may especially benefit from the use of CGM. This is because it is often difficult to make appropriate insulin dose adjustments based on SMBG data in the face of their large inter- and intraday variation in glucose readings. For some patients a reduced glycaemic variability alone, even without any improvement in HbA1c, might represent an improved outcome.

CGM can also be applied to identify and treat post-prandial hyper-glycaemia.35 Post-prandial glucose peaks vary according to meal composition, so the timing of insulin administration has to be optimal.vFactors that patients need to take into account before taking extra insulin to treat post-prandial hyperglycaemia include the residual insulin ‘on board’ from the pre-meal bolus, the direction of the glycaemic trend and the type of carbohydrate in the meal. After eating high-glycaemic-index carbohydrate foods, there is a rapid spike in glucose level. Normally there is enough insulin on board to deal with this glucose peak. Another extra bolus would impose a considerable risk of hypoglycaemia. By contrast, after a low-glycaemic-index meal, glucose absorption tends to be prolonged and an additional bolus may be needed to bring the level down to target.36 Furthermore, diabetic gastroparesis may complicate optimal timing of insulin administration.37vEarly insulin administration in respect to a delay in glucose absorption causes a sudden drop in glycaemia followed by a hyperglycaemic episode. Realtime CGM can detect post-prandial hyperglycaemia more reliably than SMBG and can be used to match insulin delivery to glucose absorption.38

Extreme Glycaemic Excursions/Hypoglycaemia

Hypoglycaemia, in particular nocturnal hypoglycaemia, occurs frequently in patients treated by means of multiple daily insulin injections or by insulin pump.39–41 Most of these hypoglycaemic episodes are asymptomatic and remain undetected by standard SMBG, as finger-prick glucose measurements are rarely performed at night.

To deal with nocturnal hypoglycaemia, CGM may be used in two different ways. First, CGM can be used in retrospect to identify the incidence and magnitude of nocturnal hypoglycaemia and guide insulin treatment accordingly. Second, most CGM devices can detect impending glycaemic excursions in realtime 20–30 minutes ahead and are equipped with an alarm function. In this way, CGM can warn the patient of emerging hypoglycaemia and allow him or her to take appropriate preventative measures.8,9 Hyperglycaemic excursions can be identified and dealt with in the same way. The alarm function represents a major advantage for patients with hypoglycaemia unawareness, allowing the patient to feel more confident. This leads to an improvement in the patient’s quality of life.42 Warning the patient against impending hypoglycaemia is especially important when driving and may be an significant tool in preserving the patient’s ability to drive.

In the recently published JDRF trial, hypoglycaemic events were infrequent in the two study groups. Only 5–10% of patients experienced at least one severe hypoglycaemic event, with no significant difference between the study groups. Despite this, it is noteworthy that in the CGM group among patients 25 years of age or older a decrease in HbA1c levels was achieved without an increase in hypoglycaemic episodes. This finding is in contrast to those of the Diabetes Control and Complication Trial, which showed an increase in hypoglycaemic events in patients who lowered their HbA1c levels. However, the JDRF trial was not powered to detect a difference in the occurrence of hypoglycaemia.1,3,32

Motivational Aspects

CGM may improve metabolic control not only by providing accurate data for the adjustment of insulin treatment but also by promoting communication between the patient and the treating physician. Motivational benefits include reinforcement of educational concepts, enhanced self-efficacy, increased flexibility in daily life and enhanced motivation for better metabolic control.43 The reduction in fear of hypoglycaemia by using realtime CGM may improve quality of life.

The Diabetes Research in Children Network (DirecNet) received very positive comments from patients using the FreeStyle Navigator CGM system (Abbott). Most subjects used the Navigator on a daily basis. More than 70% of children and their parents agreed that its use made adjusting insulin easier, showing patterns in blood glucose not seen before and clarifying how eating habits affected glycaemia.25,44

Limitations of Continuous Glucose Monitoring

Limitations Related to the Device

Currently most available CGM systems are minimally invasive and require the insertion of a needle or a microdialysis catheter into the subcutaneous adipose tissue to measure glucose in the interstitional fluid. Non-invasive CGM systems, such as the GlucoWatch Biographer (Cygnus) and the Pendra (Pendragon Medical), are no longer available and other techniques are at a pre-clinical stage.

After application of the CGM device, a first calibration can only be performed when the sensor signal is stable. A certain amount of time is required for the equilibration process between the analyte and the sensor surface. Depending on the type of sensor, this can take between two and 10 hours. The CGM sensor needs to be calibrated several times to achieve good accuracy. This is because all sensors exhibit a certain amount of signal drift as the result of a foreign body reaction exerted by the sensor or microdialysis catheter. Such a signal drift can result in a complete loss of correlation between changes in the sensor signal and glucose levels. Compensation of the drift by repeated calibration is possible for a limited period of time.5 This explains why the use of currently available CGM devices is restricted to only a few days. An advantage of the microdialysis technique used by the GlucoDay device (Menarini Diagnostics) is that the foreign body reaction is limited.

Accuracy also depends on the technological and physiological lag time. The technological lag time is device-specific and depends on sampling frequency, membrane pore size and probe dimensions. In the case of microdialysis-based systems it also depends on dialysis perfusion rate. This lag time seems to be rather consistent, not depending on fluctuations in glycaemia and insulin levels.45–47 The physiological lag time is the time needed for glucose to equilibrate between the capillary blood and interstitial fluid. This period varies from a few seconds to 15 minutes, depending on peripheral glucose utilisation, capillary blood flow and insulin levels.48 Therefore, changes of glucose concentrations in interstitial fluid do not occur at the same time as those in the blood; they lag behind. This has important implications on clinical decision-making during times when the glucose level is changing rapidly. For example, when glucose is falling rapidly, the physiological lag time leads to normal sensor glucose readings (interstitial) even when the actual blood glucose level is quite low. Capillary glucose measurements therefore remain necessary.36

To optimise CGM accuracy it is important to calibrate the device during steady-state conditions. If glycaemia is increasing rapidly, for example during the post-prandial period, the glucose level in the blood is higher than in the interstitial fluid. If the CGM device were to be calibrated after a meal, this would lead to an upward setting of the glucose sensor and would compromise the accuracy of the device in detecting hypoglycaemia.

Currently available CGM systems are approved only as an adjunct to standard SMBG and should not be used to make therapeutic decisions without verification by blood glucose measurement.

Limitations Related to the Patient

In contrast to the motivational benefits, realtime CGM may lead to an increased treatment burden and information overload. Some patients may not be able to deal with the additional data and might overcorrect changes in glycaemia. This should be a major focus of education for the patient using realtime CGM.

Poor patient adherence is an important limitation to the use of realtime CGM. The JDRF showed less benefit of CGM among patients who were eight to 14 years of age and no benefit among those 15–24 years of age.32 This observed age effect may be related to substantially lower use of sensors in the children and adolescent group compared with adults.

Imperfect adherence to many aspects of diabetes management has long been recognised as an obstacle to successful intensive treatment in adolescents and young adults. Greater parental involvement could be the reason why children in the CGM group had greater sensor use than the adolescents. At least six days of sensor use per week was the average for 83% of patients 25 years of age or older, but this percentage dropped in young people to 30% of patients 15–24 years of age and 50% of patients eight to 14 years of age.32

It is important to recognise that the participants in the JDRF trial were highly motivated and capable of using CGM technology and had a better than average metabolic control. The results therefore cannot be extrapolated to a random diabetes population.

Target Population

Patients should be well educated in order to safely use and benefit from CGM. They should be very motivated to participate in the management of their diabetes and be technologically adept. By contrast, patients who have poor metabolic control because of reluctance to perform SMBG will not benefit from the use of CGM. Patients should receive proper instructions about the use of their CGM device, calibration issues and therapeutic decision-making.

Patients who may benefit from the use of CGM include:49

  • patients with brittle diabetes with poor metabolic control and/or high glucose variability;
  • patients with hypoglycaemia unawareness and/or fear of hypoglycaemia;
  • patients with gastroparesis;
  • pregnant women with diabetes; and
  • critically ill patients.

CGM may be used as a tool to reduce glycaemic variability in patients with brittle diabetes to increase time spent in the normoglycaemic range and improve metabolic control.18,34

In patients with fear of hypoglycaemia and hypoglycaemia unawareness, realtime CGM can be used as a monitor to warn against impending hypoglycaemic events. This allows the patient to take preventative measures.42

Patients with diabetic gastroparesis may benefit from CGM to optimise the timing of their insulin administration in order to avoid glycaemic excursions.38

For pregnant women with diabetes, strict metabolic control is essential to avoid maternal and foetal complications such as macrosomia, foetal malformations, pre-term delivery and Caesarean section. CGM may therefore help to achieve normoglycaemia, optimise insulin treatment, improve metabolic control and reduce the risk of complications.50 This is particularly important during the first trimester of pregnancy.51,52

Another important and recently highly controversial issue is glycaemic control in critically ill patients. The strict euglycaemic range of 80–110mg/dl, as proposed by the Leuven trials,53,54 was criticised by more recent studies. Two multicentre studies (VISEP and GLUCONTROL) were stopped prematurely because of safety reasons (more hypoglycaemia) and lack of benefit.55–57 The NICE-SUGAR study demonstrated increased mortality in the intensive glucose control group (81–108mg/dl) compared with conventionally treated patients (<180mg/dl).58 However, correct assessment of the magnitude and duration of hyperglycemia is important, and can only be performed using CGM.59,60 CGM may be beneficial as it enables intensive care unit staff to evaluate the effect of insulin therapy on the patient’s glycaemia in real time. With CGM, strict glycaemic control can be achieved without the fear of undetected hypoglycaemic events.

Conclusion

In order to achieve tight glycaemic control, the patient with diabetes needs to perform frequent SMBG. Hypo- and hyperglycaemic episodes can be missed between glucose measurements. Furthermore, the fear of hypoglycaemia has an important impact on the patient’s quality of life.

CGM systems provide a complete picture of glucose levels throughout the day and can warn against impending glycaemic excursions. In order to use CGM systems, patients and healthcare providers need to be highly motivated, technologically adept and aware of the limitations. Patients with brittle diabetes, hypoglycaemia unawareness or gastroparesis, those who are pregnant and those who are critically ill may particularly benefit from CGM.

In the future, the incorporation of CGM in a closed-loop system – the artificial pancreas – will be a major breakthrough in diabetes care. For now, CGM may be an aid to achieve adequate metabolic control with peace of mind.

Article Information:

References

  1. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 1993;329:977–86.
  2. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 1998;352:854–65.
  3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, N Engl J Med, 2005;353:2643–53.
  4. Schütt M, Kern W, Krause U, et al.; DPV Initiative, Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria, Exp Clin Endocrinol Diabetes, 2006;114:384–8.
  5. Koschinsky T, Heinemann L, Sensors for glucose monitoring: tecnical and clinical aspects, Diabetes Metab Res Rev, 2001;17:113–23.
  6. Klonoff DC, Continuous glucose monitoring: roadmap for 21st century diabetes therapy, Diabetes Care, 2005;28:1231–9.
  7. De Block C, Manuel-y-Keenoy B, Van Gaal L, A review of current evidence with continuous glucose monitoring in patients with diabetes, J Diabetes Sci Technol, 2008;2:718–27.
  8. Bode B, Gross K, Rikalo N, et al., Alarms based on realtime sensor glucose values alert patients to hypo- and hyperglycaemia: the Guardian continuous monitoring system, Diabetes Technol Ther, 2004;6:105–13.
  9. Sparacino G, Zanderigo F, Corazza S, et al., Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series, IEEE Trans Biomed Eng, 2007;54:931–7.
  10. Bode BW, Gross TM, Thornton KR, et al., Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study, Diabetes Res Clin Pract, 1999;46:183–90.
  11. Kaufman FR, Gibson LC, Halvorson M, et al., A pilot study of the continuous glucose mintoring system: clinical decisions and glycaemic control after its use in pediatric type 1 diabetic subjects, Diabetes Care, 2001;24:2030–4.
  12. Salardi S, Zucchini S, Santoni R, et al., The glucose area under the profiles obtained with continuous glucose monitoring system relationship with HbA(1c) in pediatric type 1 diabetic patients, Diabetes Care, 2002;25:1840–4.
  13. Schiaffini R, Ciampalini P, Fierabracci A, et al., The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycaemic risk, Diabetes Metab Res Rev, 2002;18:324–9.
  14. Schaepelynck-Bélicar P, Vague P, Simonin G, et al., Improved metabolic control in diabetes adolescents using the continuous glucose monitoring system (CGMS), Diabetes Metab, 2003;29:608–12.
  15. Garg SK, Schwartz S, Edelman SV, Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes, Diabetes Care, 2004;27:734–8.
  16. Garg S, Jovanovic L, Relationship of fasting and hourly blood glucose levels to HbA1c values: Safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor, Diabetes Care, 2006;29:2644–9.
  17. Buckingham B, Beck RQ, Tamborlane WV, et al.; The Diabetes Research in Children Network (DirecNet) Study Group, Continuous glucose monitoring in children with type 1 diabetes, J Pediatr, 2007;151:388–93.
  18. Garg SK, Kelly WC, Voelmle MK, et al., Continuous home monitoring of glucose: improved control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes, Diabetes Care, 2007;30:3023–5.
  19. Bailey TS, Zisser HC, Garg SK, Reduction in haemoglobin A1c with real-time continuous glucose monitoring: Results from a 12-week observational study, Diabetes Technol Ther, 2007;9:203–10.
  20. Chase HP, Kim LM, Owen SL, et al., Continuous subcutaneous glucose monitoring in children with type 1 diabetes, Pediatrics, 2001;107:222–6.
  21. Chase HP, Roberts MD, Wightman C, et al., Use of the GlucoWatch biographer in children with type 1 diabetes, Pediatrics, 2003;111:790–94.
  22. Chico A, Vidal-Ríos P, Subirà MN, et al., The continuous glucose monitoring system is useful for detecting unrecognized hypoglycaemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control, Diabetes Care, 2003;26:1153–7.
  23. Ludvigsson J, Hanas R, Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study, Pediatrics, 2003;111:933–8.
  24. Tanenberg R, Bode B, Lane W, et al., Use of the Continuous Glucose Monitoring system to guide therapy in patients with insulin-treated diabetes: A randomized controlled trial, Mayo Clin Proc, 2004;79;1521–6.
  25. Chase HP, Beck R, Tamborlane W, et al.; The Diabetes Research in Children Network (DirecNet) Study Group, A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes, Diabetes Care, 2005;28:1101–6.
  26. Lagarde WH, Barrows FP, Davenport ML, et al., Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial, Pediatric Diabetes, 2006;7:159–64.
  27. Garg S, Zisser H, Schwartz S, et al., Improvement in glycaemic excursions with a transcutaneous, real-time continuous sensor: a randomized controlled trial, Diabetes Care, 2006;29:45–50.
  28. Deiss D, Bolinder J, Riveline JP, et al., Improved glycaemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring, Diabetes Care, 2006;29:2730–32.
  29. Deiss D, Hartmann R, Schmidt J, et al., Results of a randomized controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes, Exp Clin Endocrinol Diabetes, 2006;114:63–7.
  30. Yates K, Milton AH, Dear K, et al., Continuous glucose monitoring-guided insulin adjustments in children and adolescents on near-physiological insulin regimens, Diabetes Care, 2006;29:1512–7.
  31. Lee SW, Sweeney T, Clausen D, et al., Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycaemic control compared to multiple daily injection therapy in pump naïve patients with type 1 diabetes; single center pilot study experience, J Diabetes Sci Technol, 2007;1:400–4.
  32. Tamborlane W, Beck R, Bode B, et al.; The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Continuous glucose monitoring and intensive treatment of type 1 diabetes, N Engl J Med, 2008;359:1464–76.
  33. Brownlee M, Hirsch IB, Glycemic variability: a haemoglobin A1c-independent risk factor for diabetic complications, JAMA, 2006;295:1707–8.
  34. Kovatchev B, Clarke W, Continuous glucose monitoring (CGM) reduces the risks for hypo- and hyperglycaemia and glucose variability in diabetes, Diabetes, 2007;56 (Suppl. 1):A23.
  35. Manuel-y-Keenoy B, Vertommen J, Abrams P, et al., Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device, Diabetes Metab Res Rev, 2004;20(Suppl. 2):S24–S31.
  36. Wolpert HA, The nuts and bolts of achieving end points with real-time continuous glucose monitoring, Diabetes Care, 2008;31(Suppl. 2):S146–9.
  37. De Block CEM, De Leeuw IH, Pelckmans PA, et al., Current concepts in gastric motility in diabetes mellitus, Curr Diabetes Rev, 2006;2:113–30.
  38. Tanenberg RJ, Pfeifer MA, Continuous glucose monitoring system: a new approach to the diagnosis of diabetic gastroparesis, Diabetes Technol Ther, 2000;2(Suppl. 1):S73–80.
  39. Bode BW, Schwartz S, Stubbs HA, et al., Glycaemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values, Diabetes Care, 2005;28:2361–6.
  40. Wentholt IME, Maran A, Masurel N, et al., Nocturnal hypoglycaemia in type 1 diabetic patients, assessed with continuous clucose monitoring: frequency, duration and associations, Diabet Med, 2007;24:527–32.
  41. Amin R, Ross K, Acerini CL, et al., Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system, Diabetes Care, 2003;26:662–7.
  42. Kubiak T, Hermanns N, Schreckling H, et al., Assessment of hypoglycaemia awareness using continuous glucose monitoring, Diabet Med, 2004;21:487–90.
  43. Kruger D, Marcus AO, Psycological motivation and patient education: a role for continuous glucose monitoring, Diabetes Technol Ther, 2000;2(Suppl. 1):S93–7.
  44. The Diabetes Research in Children Network (DirecNet) Study Group, Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes, Diabetes Care, 2005;28:1929–35.
  45. Steil GM, Rebrin K, Hariri F, et al., Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia, Diabetologia, 2005;48:1833–40.
  46. Rossetti P, Porcellati F, Fanelli C, et al., Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycaemia, its recovery, and posthypoglycemic hyperglycaemia in humans, Diabetes Technol Ther, 2006;8:326–37.
  47. Boyne MS, Silver DM, Kaplan J, et al., Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor, Diabetes, 2003;52:2790–94.
  48. Rebrin K, Steil GM, Van Antwerp WP, et al., Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring, Am J Physiol, 1999;277:E561–71.
  49. De Block C, Vertommen J, Manuel-y-Keenoy B, et al., Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, technical and clinical aspects, Curr Diabetes Rev, 2008;4:159–68.
  50. Byrne EZ, Zisser HC, Jovanovic L, Continuous glucose monitoring: is it helpful in pregnancy?, Curr Diabetes Rev, 2008;4:223–6.
  51. Kestilä KK, Ekblad UU, Rönnemaa T, Continuous glucose mintoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus, Diabetes Res Clin Pract, 2007;77:174–9.
  52. Murphy HR, Rayman G, Duffield K, et al., Changes in the glycaemic profiles of women with type 1 and 2 diabetes during pregnancy, Diabetes Care, 2007;30:2785–91.
  53. Van den Berghe G, Wouters P, Weekers F, et al., Intensive insulin therapy in the critically ill patients, N Engl J Med, 2001;345:1359–67.
  54. Van den Berghe G, Wilmer A, Hermans G, et al., Intensive insulin therapy in the medical ICU, N Engl J Med, 2006;354: 449–61.
  55. Brunkhorst FM, Engel Ch, Bloos F, et al., Intensive insulin therapy and pentastarch resuscitation in severe sepsis (VISEP), N Engl J Med, 2008;358:125–39.
  56. National Institutes of Health, Glucontrol study: comparing the effects of two glucose control regimens by insulin in intensive care unit patients, NIH, 2010. Available at: www.clinicaltrials.gov/ct/show/NCT00107601 (accessed 17 June 2010).
  57. Preiser JC, Devos P, Clinical experience with tight glucose control by intensive insulin therapy, Crit Care Med, 2007;35(Suppl.):503–5.
  58. Finfer S, Chittock DR, Su SY, et al., Intensive versus conventional glucose control in critically ill patients (NICE-SUGAR), N Engl J Med, 2009;360:1346–9.
  59. De Block C, Van Gaal L, Manuel-y-Keenoy B, et al., Intensive Insulin Therapy in the Intensive Care Unit: Assessment by continuous glucose monitoring, Diabetes Care, 2006;29:1750–56.
  60. De Block C, Manuel-y-Keenoy B, Rogiers P, et al., Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review, Curr Diabetes Rev, 2008;4:234–44.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72